HEADER HYDROLASE 18-OCT-04 1XS7 TITLE CRYSTAL STRUCTURE OF A CYCLOAMIDE-URETHANE-DERIVED NOVEL INHIBITOR TITLE 2 BOUND TO HUMAN BRAIN MEMAPSIN 2 (BETA-SECRETASE). COMPND MOL_ID: 1; COMPND 2 MOLECULE: BETA-SECRETASE 1; COMPND 3 CHAIN: D; COMPND 4 SYNONYM: BETA-SITE APP CLEAVING ENZYME 1, BETA-SITE AMYLOID PRECURSOR COMPND 5 PROTEIN CLEAVING ENZYME 1, ASPARTYL PROTEASE 2, ASP 2, ASP2, COMPND 6 MEMBRANE-ASSOCIATED ASPARTIC PROTEASE 2, MEMAPSIN-2; COMPND 7 EC: 3.4.23.46; COMPND 8 ENGINEERED: YES SOURCE MOL_ID: 1; SOURCE 2 ORGANISM_SCIENTIFIC: HOMO SAPIENS; SOURCE 3 ORGANISM_COMMON: HUMAN; SOURCE 4 ORGANISM_TAXID: 9606; SOURCE 5 GENE: BACE1, BACE; SOURCE 6 EXPRESSION_SYSTEM: ESCHERICHIA COLI BL21; SOURCE 7 EXPRESSION_SYSTEM_TAXID: 511693; SOURCE 8 EXPRESSION_SYSTEM_STRAIN: BL21; SOURCE 9 EXPRESSION_SYSTEM_VECTOR_TYPE: PET11A; SOURCE 10 EXPRESSION_SYSTEM_PLASMID: PLASMID KEYWDS BETA SECRETASE, MEMAPSIN2, BACE, ASP2, ASPARTIC PROTEASE, ACID KEYWDS 2 PROTEASE, ALZHEIMER'S DISEASE, DRUG DESIGN, HYDROLASE EXPDTA X-RAY DIFFRACTION AUTHOR A.GHOSH,T.DEVASAMUDRAM,L.HONG,C.DEZUTTER,X.XU,V.WEERASENA,G.KOELSCH, AUTHOR 2 G.BILCER,J.TANG REVDAT 3 23-AUG-23 1XS7 1 COMPND REMARK HETNAM REVDAT 2 24-FEB-09 1XS7 1 VERSN REVDAT 1 21-DEC-04 1XS7 0 JRNL AUTH A.K.GHOSH,T.DEVASAMUDRAM,L.HONG,C.DEZUTTER,X.XU,V.WEERASENA, JRNL AUTH 2 G.KOELSCH,G.BILCER,J.TANG JRNL TITL STRUCTURE-BASED DESIGN OF CYCLOAMIDE-URETHANE-DERIVED NOVEL JRNL TITL 2 INHIBITORS OF HUMAN BRAIN MEMAPSIN 2 (BETA-SECRETASE). JRNL REF BIOORG.MED.CHEM.LETT. V. 15 15 2005 JRNL REFN ISSN 0960-894X JRNL PMID 15582402 JRNL DOI 10.1016/J.BMCL.2004.10.084 REMARK 2 REMARK 2 RESOLUTION. 2.80 ANGSTROMS. REMARK 3 REMARK 3 REFINEMENT. REMARK 3 PROGRAM : CNS 1.0 REMARK 3 AUTHORS : BRUNGER,ADAMS,CLORE,DELANO,GROS,GROSSE- REMARK 3 : KUNSTLEVE,JIANG,KUSZEWSKI,NILGES,PANNU, REMARK 3 : READ,RICE,SIMONSON,WARREN REMARK 3 REMARK 3 REFINEMENT TARGET : ENGH & HUBER REMARK 3 REMARK 3 DATA USED IN REFINEMENT. REMARK 3 RESOLUTION RANGE HIGH (ANGSTROMS) : 2.80 REMARK 3 RESOLUTION RANGE LOW (ANGSTROMS) : 50.00 REMARK 3 DATA CUTOFF (SIGMA(F)) : 0.000 REMARK 3 DATA CUTOFF HIGH (ABS(F)) : NULL REMARK 3 DATA CUTOFF LOW (ABS(F)) : NULL REMARK 3 COMPLETENESS (WORKING+TEST) (%) : 76.0 REMARK 3 NUMBER OF REFLECTIONS : 36513 REMARK 3 REMARK 3 FIT TO DATA USED IN REFINEMENT. REMARK 3 CROSS-VALIDATION METHOD : THROUGHOUT REMARK 3 FREE R VALUE TEST SET SELECTION : RANDOM REMARK 3 R VALUE (WORKING SET) : NULL REMARK 3 FREE R VALUE : NULL REMARK 3 FREE R VALUE TEST SET SIZE (%) : NULL REMARK 3 FREE R VALUE TEST SET COUNT : 1832 REMARK 3 ESTIMATED ERROR OF FREE R VALUE : NULL REMARK 3 REMARK 3 FIT IN THE HIGHEST RESOLUTION BIN. REMARK 3 TOTAL NUMBER OF BINS USED : NULL REMARK 3 BIN RESOLUTION RANGE HIGH (A) : NULL REMARK 3 BIN RESOLUTION RANGE LOW (A) : NULL REMARK 3 BIN COMPLETENESS (WORKING+TEST) (%) : NULL REMARK 3 REFLECTIONS IN BIN (WORKING SET) : NULL REMARK 3 BIN R VALUE (WORKING SET) : NULL REMARK 3 BIN FREE R VALUE : NULL REMARK 3 BIN FREE R VALUE TEST SET SIZE (%) : NULL REMARK 3 BIN FREE R VALUE TEST SET COUNT : NULL REMARK 3 ESTIMATED ERROR OF BIN FREE R VALUE : NULL REMARK 3 REMARK 3 NUMBER OF NON-HYDROGEN ATOMS USED IN REFINEMENT. REMARK 3 PROTEIN ATOMS : 3053 REMARK 3 NUCLEIC ACID ATOMS : 0 REMARK 3 HETEROGEN ATOMS : 52 REMARK 3 SOLVENT ATOMS : 0 REMARK 3 REMARK 3 B VALUES. REMARK 3 FROM WILSON PLOT (A**2) : NULL REMARK 3 MEAN B VALUE (OVERALL, A**2) : NULL REMARK 3 OVERALL ANISOTROPIC B VALUE. REMARK 3 B11 (A**2) : NULL REMARK 3 B22 (A**2) : NULL REMARK 3 B33 (A**2) : NULL REMARK 3 B12 (A**2) : NULL REMARK 3 B13 (A**2) : NULL REMARK 3 B23 (A**2) : NULL REMARK 3 REMARK 3 ESTIMATED COORDINATE ERROR. REMARK 3 ESD FROM LUZZATI PLOT (A) : NULL REMARK 3 ESD FROM SIGMAA (A) : NULL REMARK 3 LOW RESOLUTION CUTOFF (A) : NULL REMARK 3 REMARK 3 CROSS-VALIDATED ESTIMATED COORDINATE ERROR. REMARK 3 ESD FROM C-V LUZZATI PLOT (A) : NULL REMARK 3 ESD FROM C-V SIGMAA (A) : NULL REMARK 3 REMARK 3 RMS DEVIATIONS FROM IDEAL VALUES. REMARK 3 BOND LENGTHS (A) : 0.007 REMARK 3 BOND ANGLES (DEGREES) : 1.400 REMARK 3 DIHEDRAL ANGLES (DEGREES) : NULL REMARK 3 IMPROPER ANGLES (DEGREES) : NULL REMARK 3 REMARK 3 ISOTROPIC THERMAL MODEL : NULL REMARK 3 REMARK 3 ISOTROPIC THERMAL FACTOR RESTRAINTS. RMS SIGMA REMARK 3 MAIN-CHAIN BOND (A**2) : NULL ; NULL REMARK 3 MAIN-CHAIN ANGLE (A**2) : NULL ; NULL REMARK 3 SIDE-CHAIN BOND (A**2) : NULL ; NULL REMARK 3 SIDE-CHAIN ANGLE (A**2) : NULL ; NULL REMARK 3 REMARK 3 BULK SOLVENT MODELING. REMARK 3 METHOD USED : NULL REMARK 3 KSOL : NULL REMARK 3 BSOL : NULL REMARK 3 REMARK 3 NCS MODEL : NULL REMARK 3 REMARK 3 NCS RESTRAINTS. RMS SIGMA/WEIGHT REMARK 3 GROUP 1 POSITIONAL (A) : NULL ; NULL REMARK 3 GROUP 1 B-FACTOR (A**2) : NULL ; NULL REMARK 3 REMARK 3 PARAMETER FILE 1 : NULL REMARK 3 TOPOLOGY FILE 1 : NULL REMARK 3 REMARK 3 OTHER REFINEMENT REMARKS: NULL REMARK 4 REMARK 4 1XS7 COMPLIES WITH FORMAT V. 3.30, 13-JUL-11 REMARK 100 REMARK 100 THIS ENTRY HAS BEEN PROCESSED BY RCSB ON 07-DEC-04. REMARK 100 THE DEPOSITION ID IS D_1000030706. REMARK 200 REMARK 200 EXPERIMENTAL DETAILS REMARK 200 EXPERIMENT TYPE : X-RAY DIFFRACTION REMARK 200 DATE OF DATA COLLECTION : 12-OCT-02 REMARK 200 TEMPERATURE (KELVIN) : 100 REMARK 200 PH : 6.2 REMARK 200 NUMBER OF CRYSTALS USED : 1 REMARK 200 REMARK 200 SYNCHROTRON (Y/N) : N REMARK 200 RADIATION SOURCE : ROTATING ANODE REMARK 200 BEAMLINE : NULL REMARK 200 X-RAY GENERATOR MODEL : RIGAKU RU300 REMARK 200 MONOCHROMATIC OR LAUE (M/L) : M REMARK 200 WAVELENGTH OR RANGE (A) : 1.5418 REMARK 200 MONOCHROMATOR : NI MIRROR + NI FILTER REMARK 200 OPTICS : MIRRORS REMARK 200 REMARK 200 DETECTOR TYPE : IMAGE PLATE REMARK 200 DETECTOR MANUFACTURER : RIGAKU RAXIS IV REMARK 200 INTENSITY-INTEGRATION SOFTWARE : DENZO REMARK 200 DATA SCALING SOFTWARE : SCALEPACK REMARK 200 REMARK 200 NUMBER OF UNIQUE REFLECTIONS : 40045 REMARK 200 RESOLUTION RANGE HIGH (A) : 2.800 REMARK 200 RESOLUTION RANGE LOW (A) : 50.000 REMARK 200 REJECTION CRITERIA (SIGMA(I)) : -3.000 REMARK 200 REMARK 200 OVERALL. REMARK 200 COMPLETENESS FOR RANGE (%) : 79.0 REMARK 200 DATA REDUNDANCY : NULL REMARK 200 R MERGE (I) : NULL REMARK 200 R SYM (I) : NULL REMARK 200 FOR THE DATA SET : NULL REMARK 200 REMARK 200 IN THE HIGHEST RESOLUTION SHELL. REMARK 200 HIGHEST RESOLUTION SHELL, RANGE HIGH (A) : 2.80 REMARK 200 HIGHEST RESOLUTION SHELL, RANGE LOW (A) : 2.90 REMARK 200 COMPLETENESS FOR SHELL (%) : 54.0 REMARK 200 DATA REDUNDANCY IN SHELL : NULL REMARK 200 R MERGE FOR SHELL (I) : NULL REMARK 200 R SYM FOR SHELL (I) : NULL REMARK 200 FOR SHELL : NULL REMARK 200 REMARK 200 DIFFRACTION PROTOCOL: SINGLE WAVELENGTH REMARK 200 METHOD USED TO DETERMINE THE STRUCTURE: MOLECULAR REPLACEMENT REMARK 200 SOFTWARE USED: AMORE REMARK 200 STARTING MODEL: 1M4H REMARK 200 REMARK 200 REMARK: NULL REMARK 280 REMARK 280 CRYSTAL REMARK 280 SOLVENT CONTENT, VS (%): 55.00 REMARK 280 MATTHEWS COEFFICIENT, VM (ANGSTROMS**3/DA): 2.90 REMARK 280 REMARK 280 CRYSTALLIZATION CONDITIONS: 14% PEG 8000, 0.1M CACODYLATE, PH 6.2, REMARK 280 VAPOR DIFFUSION, HANGING DROP, TEMPERATURE 293K REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY REMARK 290 SYMMETRY OPERATORS FOR SPACE GROUP: P 1 21 1 REMARK 290 REMARK 290 SYMOP SYMMETRY REMARK 290 NNNMMM OPERATOR REMARK 290 1555 X,Y,Z REMARK 290 2555 -X,Y+1/2,-Z REMARK 290 REMARK 290 WHERE NNN -> OPERATOR NUMBER REMARK 290 MMM -> TRANSLATION VECTOR REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY TRANSFORMATIONS REMARK 290 THE FOLLOWING TRANSFORMATIONS OPERATE ON THE ATOM/HETATM REMARK 290 RECORDS IN THIS ENTRY TO PRODUCE CRYSTALLOGRAPHICALLY REMARK 290 RELATED MOLECULES. REMARK 290 SMTRY1 1 1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 1 0.000000 1.000000 0.000000 0.00000 REMARK 290 SMTRY3 1 0.000000 0.000000 1.000000 0.00000 REMARK 290 SMTRY1 2 -1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 2 0.000000 1.000000 0.000000 43.90350 REMARK 290 SMTRY3 2 0.000000 0.000000 -1.000000 0.00000 REMARK 290 REMARK 290 REMARK: NULL REMARK 300 REMARK 300 BIOMOLECULE: 1 REMARK 300 SEE REMARK 350 FOR THE AUTHOR PROVIDED AND/OR PROGRAM REMARK 300 GENERATED ASSEMBLY INFORMATION FOR THE STRUCTURE IN REMARK 300 THIS ENTRY. THE REMARK MAY ALSO PROVIDE INFORMATION ON REMARK 300 BURIED SURFACE AREA. REMARK 350 REMARK 350 COORDINATES FOR A COMPLETE MULTIMER REPRESENTING THE KNOWN REMARK 350 BIOLOGICALLY SIGNIFICANT OLIGOMERIZATION STATE OF THE REMARK 350 MOLECULE CAN BE GENERATED BY APPLYING BIOMT TRANSFORMATIONS REMARK 350 GIVEN BELOW. BOTH NON-CRYSTALLOGRAPHIC AND REMARK 350 CRYSTALLOGRAPHIC OPERATIONS ARE GIVEN. REMARK 350 REMARK 350 BIOMOLECULE: 1 REMARK 350 AUTHOR DETERMINED BIOLOGICAL UNIT: MONOMERIC REMARK 350 APPLY THE FOLLOWING TO CHAINS: D REMARK 350 BIOMT1 1 1.000000 0.000000 0.000000 0.00000 REMARK 350 BIOMT2 1 0.000000 1.000000 0.000000 0.00000 REMARK 350 BIOMT3 1 0.000000 0.000000 1.000000 0.00000 REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: TORSION ANGLES REMARK 500 REMARK 500 TORSION ANGLES OUTSIDE THE EXPECTED RAMACHANDRAN REGIONS: REMARK 500 (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN IDENTIFIER; REMARK 500 SSEQ=SEQUENCE NUMBER; I=INSERTION CODE). REMARK 500 REMARK 500 STANDARD TABLE: REMARK 500 FORMAT:(10X,I3,1X,A3,1X,A1,I4,A1,4X,F7.2,3X,F7.2) REMARK 500 REMARK 500 EXPECTED VALUES: GJ KLEYWEGT AND TA JONES (1996). PHI/PSI- REMARK 500 CHOLOGY: RAMACHANDRAN REVISITED. STRUCTURE 4, 1395 - 1400 REMARK 500 REMARK 500 M RES CSSEQI PSI PHI REMARK 500 PHE D 47P 60.90 -112.61 REMARK 500 VAL D 48P -31.87 -33.51 REMARK 500 GLN D 53 79.96 -115.60 REMARK 500 ARG D 64 56.93 29.87 REMARK 500 THR D 72 -36.39 -35.04 REMARK 500 LYS D 75 137.68 178.40 REMARK 500 PHE D 108 -58.94 -134.16 REMARK 500 ASN D 114 14.49 84.45 REMARK 500 ALA D 122 -164.36 -73.02 REMARK 500 GLU D 125 -49.27 -23.05 REMARK 500 GLU D 134 110.26 -37.77 REMARK 500 THR D 144 -169.42 -125.80 REMARK 500 VAL D 146 120.24 -21.52 REMARK 500 GLN D 163 -19.55 -41.98 REMARK 500 ALA D 168 53.14 -97.42 REMARK 500 VAL D 170 76.02 -109.73 REMARK 500 ARG D 194 -75.57 -57.01 REMARK 500 TRP D 197 -76.52 -118.75 REMARK 500 ASP D 223 -67.95 86.68 REMARK 500 LYS D 224 160.41 178.26 REMARK 500 LYS D 238 -71.56 -38.21 REMARK 500 LEU D 263 33.01 -96.49 REMARK 500 THR D 292 149.06 -38.31 REMARK 500 THR D 314 67.51 26.24 REMARK 500 SER D 315 -120.84 -113.40 REMARK 500 ALA D 323 40.95 -100.30 REMARK 500 LYS D 350 55.49 33.93 REMARK 500 ALA D 358 6.70 -67.19 REMARK 500 ASP D 378 63.06 32.56 REMARK 500 REMARK 500 REMARK: NULL REMARK 800 REMARK 800 SITE REMARK 800 SITE_IDENTIFIER: AC1 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE MMI D 386 DBREF 1XS7 D 45P 385 UNP P56817 BACE1_HUMAN 58 446 SEQRES 1 D 389 GLY SER PHE VAL GLU MET VAL ASP ASN LEU ARG GLY LYS SEQRES 2 D 389 SER GLY GLN GLY TYR TYR VAL GLU MET THR VAL GLY SER SEQRES 3 D 389 PRO PRO GLN THR LEU ASN ILE LEU VAL ASP THR GLY SER SEQRES 4 D 389 SER ASN PHE ALA VAL GLY ALA ALA PRO HIS PRO PHE LEU SEQRES 5 D 389 HIS ARG TYR TYR GLN ARG GLN LEU SER SER THR TYR ARG SEQRES 6 D 389 ASP LEU ARG LYS GLY VAL TYR VAL PRO TYR THR GLN GLY SEQRES 7 D 389 LYS TRP GLU GLY GLU LEU GLY THR ASP LEU VAL SER ILE SEQRES 8 D 389 PRO HIS GLY PRO ASN VAL THR VAL ARG ALA ASN ILE ALA SEQRES 9 D 389 ALA ILE THR GLU SER ASP LYS PHE PHE ILE ASN GLY SER SEQRES 10 D 389 ASN TRP GLU GLY ILE LEU GLY LEU ALA TYR ALA GLU ILE SEQRES 11 D 389 ALA ARG PRO ASP ASP SER LEU GLU PRO PHE PHE ASP SER SEQRES 12 D 389 LEU VAL LYS GLN THR HIS VAL PRO ASN LEU PHE SER LEU SEQRES 13 D 389 GLN LEU CYS GLY ALA GLY PHE PRO LEU ASN GLN SER GLU SEQRES 14 D 389 VAL LEU ALA SER VAL GLY GLY SER MET ILE ILE GLY GLY SEQRES 15 D 389 ILE ASP HIS SER LEU TYR THR GLY SER LEU TRP TYR THR SEQRES 16 D 389 PRO ILE ARG ARG GLU TRP TYR TYR GLU VAL ILE ILE VAL SEQRES 17 D 389 ARG VAL GLU ILE ASN GLY GLN ASP LEU LYS MET ASP CYS SEQRES 18 D 389 LYS GLU TYR ASN TYR ASP LYS SER ILE VAL ASP SER GLY SEQRES 19 D 389 THR THR ASN LEU ARG LEU PRO LYS LYS VAL PHE GLU ALA SEQRES 20 D 389 ALA VAL LYS SER ILE LYS ALA ALA SER SER THR GLU LYS SEQRES 21 D 389 PHE PRO ASP GLY PHE TRP LEU GLY GLU GLN LEU VAL CYS SEQRES 22 D 389 TRP GLN ALA GLY THR THR PRO TRP ASN ILE PHE PRO VAL SEQRES 23 D 389 ILE SER LEU TYR LEU MET GLY GLU VAL THR ASN GLN SER SEQRES 24 D 389 PHE ARG ILE THR ILE LEU PRO GLN GLN TYR LEU ARG PRO SEQRES 25 D 389 VAL GLU ASP VAL ALA THR SER GLN ASP ASP CYS TYR LYS SEQRES 26 D 389 PHE ALA ILE SER GLN SER SER THR GLY THR VAL MET GLY SEQRES 27 D 389 ALA VAL ILE MET GLU GLY PHE TYR VAL VAL PHE ASP ARG SEQRES 28 D 389 ALA ARG LYS ARG ILE GLY PHE ALA VAL SER ALA CYS HIS SEQRES 29 D 389 VAL HIS ASP GLU PHE ARG THR ALA ALA VAL GLU GLY PRO SEQRES 30 D 389 PHE VAL THR LEU ASP MET GLU ASP CYS GLY TYR ASN HET MMI D 386 52 HETNAM MMI N-[(4S,5S,7R)-8-({(S)-1-[(BENZYLAMINO)OXOMETHYL]-2- HETNAM 2 MMI METHYLPROPYL}AMINO)-5-HYDROXY-2,7-DIMETHYL-8-OXO-OCT- HETNAM 3 MMI 4-YL]-(4S,7S)-4 -ISOPROPYL-2,5,9-TRIOXO-1-OXA-3,6,10- HETNAM 4 MMI TRIAZACYCLOHEXADECANE-7-CARBOXAMIDE HETSYN MMI MMI-175 FORMUL 2 MMI C38 H62 N6 O8 HELIX 1 1 GLN D 53 SER D 57 5 5 HELIX 2 2 TYR D 123 ALA D 127 5 5 HELIX 3 3 PRO D 135 THR D 144 1 10 HELIX 4 4 ASN D 162 ALA D 168 1 7 HELIX 5 5 ASP D 180 SER D 182 5 3 HELIX 6 6 ASP D 216 ASN D 221 5 6 HELIX 7 7 LYS D 238 SER D 252 1 15 HELIX 8 8 PRO D 258 LEU D 263 1 6 HELIX 9 9 PRO D 276 PHE D 280 5 5 HELIX 10 10 LEU D 301 TYR D 305 1 5 HELIX 11 11 ALA D 335 GLY D 340 1 6 SHEET 1 A 8 LEU D 6 LYS D 9 0 SHEET 2 A 8 GLY D 13 VAL D 20 -1 O TYR D 15 N ARG D 7 SHEET 3 A 8 GLN D 25 ASP D 32 -1 O ILE D 29 N VAL D 16 SHEET 4 A 8 GLY D 117 GLY D 120 1 O GLY D 117 N LEU D 30 SHEET 5 A 8 PHE D 38 GLY D 41 -1 N ALA D 39 O ILE D 118 SHEET 6 A 8 THR D 94 ASP D 106 1 O ALA D 100 N PHE D 38 SHEET 7 A 8 GLY D 74 SER D 86 -1 N GLU D 77 O GLU D 104 SHEET 8 A 8 ARG D 61 TYR D 71 -1 N TYR D 71 O GLY D 74 SHEET 1 B 4 LEU D 6 LYS D 9 0 SHEET 2 B 4 GLY D 13 VAL D 20 -1 O TYR D 15 N ARG D 7 SHEET 3 B 4 GLY D 74 SER D 86 -1 O SER D 86 N THR D 19 SHEET 4 B 4 ARG D 61 TYR D 71 -1 N TYR D 71 O GLY D 74 SHEET 1 C 5 GLY D 172 ILE D 176 0 SHEET 2 C 5 PHE D 150 LEU D 154 -1 N GLN D 153 O SER D 173 SHEET 3 C 5 PHE D 341 ASP D 346 -1 O VAL D 343 N LEU D 152 SHEET 4 C 5 ARG D 351 SER D 357 -1 O GLY D 353 N VAL D 344 SHEET 5 C 5 TYR D 184 PRO D 192 -1 N THR D 191 O ILE D 352 SHEET 1 D 5 GLU D 200 VAL D 201 0 SHEET 2 D 5 SER D 225 ASP D 228 -1 O SER D 225 N VAL D 201 SHEET 3 D 5 THR D 331 GLY D 334 1 O MET D 333 N ILE D 226 SHEET 4 D 5 LEU D 234 PRO D 237 -1 N ARG D 235 O VAL D 332 SHEET 5 D 5 ILE D 324 SER D 327 1 O SER D 325 N LEU D 236 SHEET 1 E 5 GLN D 211 ASP D 212 0 SHEET 2 E 5 ILE D 203 ILE D 208 -1 N ILE D 208 O GLN D 211 SHEET 3 E 5 ILE D 283 MET D 288 -1 O TYR D 286 N ARG D 205 SHEET 4 E 5 SER D 295 ILE D 300 -1 O ILE D 298 N LEU D 285 SHEET 5 E 5 ALA D 369 PHE D 374 -1 O GLU D 371 N ARG D 297 SHEET 1 F 3 VAL D 268 TRP D 270 0 SHEET 2 F 3 ASP D 318 PHE D 322 -1 O ASP D 318 N TRP D 270 SHEET 3 F 3 LEU D 306 VAL D 309 -1 N ARG D 307 O LYS D 321 SSBOND 1 CYS D 155 CYS D 359 1555 1555 2.76 SSBOND 2 CYS D 217 CYS D 382 1555 1555 2.84 SSBOND 3 CYS D 269 CYS D 319 1555 1555 2.90 CISPEP 1 SER D 22 PRO D 23 0 -0.26 CISPEP 2 ARG D 128 PRO D 129 0 0.08 CISPEP 3 GLY D 372 PRO D 373 0 0.05 SITE 1 AC1 15 ASP D 32 GLY D 34 SER D 35 TYR D 71 SITE 2 AC1 15 THR D 72 GLN D 73 TRP D 115 ILE D 126 SITE 3 AC1 15 TYR D 198 ASP D 228 GLY D 230 THR D 231 SITE 4 AC1 15 THR D 232 ASN D 233 ARG D 235 CRYST1 85.839 87.807 130.644 90.00 89.81 90.00 P 1 21 1 2 ORIGX1 1.000000 0.000000 0.000000 0.00000 ORIGX2 0.000000 1.000000 0.000000 0.00000 ORIGX3 0.000000 0.000000 1.000000 0.00000 SCALE1 0.011650 0.000000 -0.000039 0.00000 SCALE2 0.000000 0.011389 0.000000 0.00000 SCALE3 0.000000 0.000000 0.007654 0.00000